Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ...

According to InvestingPro data, GSK maintains a strong financial health score, positioning it well for strategic acquisitions. IDRx's lead molecule, IDRX-42, is an investigational tyrosine kinase ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision ...

GSK completes acquisition of IDRx, Inc. GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company ...

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $74.88 billion and impressive gross profit margins of 71.81%, announced the completion of its ...

(Alliance News) - GSK PLC on Monday said it has completed the acquisition of Boston, Massachusetts-based precision therapeutics firm IDRx Inc, adding to its growing portfolio of treatments for ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...